Aurobindo shares rose over 1.5% after the announcement, with the deal expected to complete by the end of June.
Aurobindo Pharma shares saw a gain of over 1.5% following the significant announcement of receiving US regulatory approval for its acquisition of Lannett. This strategic development is poised to strengthen the company's market position, with the completion of the deal…
Market Samachar is a news aggregator. This article was originally published by NDTV Profit - Latest. Tap the button above to read the full story on their site.